FYC - ETF AI Analysis
Top Page
First Trust Small Cap Growth AlphaDEX Fund (FYC)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The fund has delivered strong gains so far this year, showing solid momentum in its small-cap growth strategy.
Top Holdings Showing Strong Gains
Many of the largest positions have posted strong year-to-date gains, which has helped lift the ETF’s overall results.
Broad Sector Diversification
Holdings are spread across many sectors, with meaningful exposure to health care, technology, industrials, and financials, helping reduce reliance on any single industry.
Negative Factors
High Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are used to cover fees.
Heavy U.S. Concentration
Almost all assets are invested in U.S. companies, offering little geographic diversification if the U.S. market weakens.
Short-Term Performance Bumpiness
The ETF has recently experienced a small short-term pullback, which highlights that returns can be volatile over shorter periods.
FYC vs. SPDR S&P 500 ETF (SPY)
AUM1.39B
RegionNorth America
Expense Ratio0.70%
Beta1.12
IssuerFirst Trust
Inception DateApr 19, 2011
Dividend Yield0.18%
Asset ClassEquity
Index TrackedNASDAQ AlphaDEX Small Cap Growth Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume65,974
30 Day Avg. Volume74,446
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
158.57Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering259
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FYC Summary
The First Trust Small Cap Growth AlphaDEX Fund (FYC) is an ETF that follows the NASDAQ AlphaDEX Small Cap Growth Index, focusing on smaller U.S. companies that are trying to grow quickly. It spreads your money across many sectors, with a lot in health care, technology, and industrials. Some of its holdings include Oscar Health and Remitly Global. An investor might choose this ETF to seek higher long-term growth and to diversify beyond large, well-known companies. A key risk is that small-cap stocks can be very volatile, so the fund’s value can rise and fall sharply with the market.
How much will it cost me?The expense ratio for the First Trust Small Cap Growth AlphaDEX Fund (FYC) is 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because the fund uses an actively managed strategy to select stocks based on growth factors, rather than passively tracking an index.
What would affect this ETF?The First Trust Small Cap Growth AlphaDEX Fund (FYC) could benefit from strong economic growth in the U.S., which often supports small-cap companies, as well as advancements in sectors like health care, technology, and industrials where the ETF has significant exposure. However, rising interest rates or economic slowdowns could negatively impact small-cap growth stocks, as these companies often rely on borrowing to fund expansion and are more sensitive to market volatility. Regulatory changes in key sectors like health care or technology could also pose risks to the fund’s performance.
FYC Top 10 Holdings
FYC is leaning hard into U.S. small-cap health care, with names like Twist Bioscience and 10x Genomics acting as the fund’s turbochargers, showing rising momentum despite shaky profitability. NeoGenomics and Aveanna Healthcare are also climbing, but their heavy debt and thin margins mean they can add volatility as easily as they add gains. On the tech and fintech side, RingCentral and Remitly are steady-to-rising contributors, though rich valuations could cap their upside. Overall, the ETF is a U.S.-focused, health-care-heavy growth bet with a few tech names helping steer the ship.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| 10x Genomics | 1.05% | $14.57M | $9.47B | 465.16% | 60 Neutral | |
| RingCentral | 1.05% | $14.50M | $6.14B | 133.16% | 63 Neutral | |
| Twist Bioscience | 0.97% | $13.36M | $9.42B | 430.48% | 43 Neutral | |
| Aveanna Healthcare Holdings | 0.92% | $12.79M | $3.11B | 76.48% | 58 Neutral | |
| Precigen | 0.91% | $12.53M | $2.66B | 94.63% | 48 Neutral | |
| NeoGenomics | 0.90% | $12.47M | $2.43B | 133.54% | 55 Neutral | |
| Calumet Specialty Products | 0.89% | $12.37M | $5.10B | 209.14% | 51 Neutral | |
| Acadian Asset Management | 0.87% | $11.98M | $3.17B | 84.55% | 66 Neutral | |
| First Advantage | 0.83% | $11.47M | $3.70B | 38.38% | 51 Neutral | |
| Lifestance Health Group | 0.83% | $11.47M | $4.89B | 148.35% | 61 Neutral |
FYC Technical Analysis
Neutral
―
Price Trends
120.35
Negative
118.51
Negative
109.29
Positive
Market Momentum
-1.25
Positive
41.11
Neutral
38.12
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FYC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 118.96, equal to the 50-day MA of 120.35, and equal to the 200-day MA of 109.29, indicating a neutral trend. The MACD of -1.25 indicates Positive momentum. The RSI at 41.11 is Neutral, neither overbought nor oversold. The STOCH value of 38.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FYC.
FYC Peer Comparison
Comparison Results
Performance Comparison
FYC
First Trust Small Cap Growth AlphaDEX Fund
117.02
25.93
28.47%
FNDA
Schwab Fundamental US Small Co. Index ETF
―
―
―
IJT
iShares S&P Small-Cap 600 Growth ETF
―
―
―
SLYG
SPDR S&P 600 Small Cap Growth ETF
―
―
―
VTWG
Vanguard Russell 2000 Growth ETF
―
―
―
VIOG
Vanguard S&P Small-Cap 600 Growth ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents